QLT Inc. (QLTI) Reports Positive QLT091001 Phase 1b Results
Tweet
Share
E-mailGet Alerts QLTI Hot Sheet
Join SI Premium – FREE
QLT Inc. (Nasdaq: QLTI) reports positive results from a Phase 1b proof-of-concept clinical trial of QLT091001 for the treatment of Leber Congenital Amaurosis (LCA).
From the release: "Analysis of data from 12 subjects with LCA who were treated with QLT091001 for seven days has been conducted to determine improvements in two distinct measures of visual function: visual acuity and visual fields. The study demonstrated that treatment with QLT091001 resulted in clinically meaningful improvement in either or both visual acuity and visual fields in 8 of the 12 subjects. Statistically significant and clinically meaningful changes in visual fields from baseline values were also noted in a conservative analysis subset of 7 subjects across this heterogeneous low vision population."
From the release: "Analysis of data from 12 subjects with LCA who were treated with QLT091001 for seven days has been conducted to determine improvements in two distinct measures of visual function: visual acuity and visual fields. The study demonstrated that treatment with QLT091001 resulted in clinically meaningful improvement in either or both visual acuity and visual fields in 8 of the 12 subjects. Statistically significant and clinically meaningful changes in visual fields from baseline values were also noted in a conservative analysis subset of 7 subjects across this heterogeneous low vision population."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shake Shack (SHAK) Announces Resignation of Jonathan Sokoloff from Board, Cuts Board Size to 10 from 11
- SQL Technologies (SKYX) Reduces Payment to GE Trademark to $1M, Enters Note Convertible at $1.07/sh
- 89bio Inc. (ETNB) Appoints Martin Babler to its Board
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
